Clinical significance of annexin A2 downregulation in oral squamous cell carcinoma

Head and Neck

Volumn 33, Issue 12, 2011, Pages 1708-1714

  Rodrigo, Juan P ^a,b   Lequerica Fernández, Paloma ^b,c   Rosado, Pablo ^a   Allonca, Eva ^b   García Pedrero, Juana M ^b   De Vicente, Juan C ^a,b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c HOSPITAL SAN AGUSTÍN   (Spain)

Author keywords

Annexin A2; immunohistochemistry; oral cancer; oral squamous cell carcinoma; prognosis

Indexed keywords

LIPOCORTIN 2;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; ILLNESS TRAJECTORY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A2; CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 81255161301     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21661     Document Type: Article

References (47)

1. Cancer Facts and Figures 2003. American Cancer Society. Available at:. Accessed March 15, 2010.
2. Kademani D,. Oral cancer. Mayo Clin Proc 2007; 82: 878-887. (Pubitemid 47015470)
3. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
4. Kornberg LJ, Villaret D, Popp M, et al. Gene expression profiling in squamous cell carcinoma of the oral cavity shows abnormalities in several signaling pathways. Laryngoscope 2005; 115: 690-698. (Pubitemid 40530023)
5. Shukla S, Pranay A, D'Cruz AK, Chaturvedi P, Kane SV, Zingde SM,. Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response. Cancer Biomark 2009; 5: 127-135.
6. + signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005; 6: 449-461. (Pubitemid 40780557)
7. Reeves SA, Chavez-Kappel C, Davis R, Rosenblum M, Israel MA,. Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res 1992; 52: 6871-6876. (Pubitemid 23006292)
8. Frohlich M, Motté P, Galvin K, Takahashi H, Wands J, Ozturk M,. Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma. Mol Cell Biol 1990; 10: 3216-3223.
9. Díaz VM, Hurtado M, Thomson TM, Reventõs J, Paciucci R,. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cells activates plasminogen and promotes invasion in vitro. Gut 2004; 53: 993-1000. (Pubitemid 38824158)
10. Emoto K, Sawada H, Yamada Y, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 2001; 21: 1339-1345.
11. Emoto K, Yamada Y, Sawada H, et al. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001; 92: 1419-1426. (Pubitemid 32947825)
12. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC,. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol 2006; 81: 146-156. (Pubitemid 44715786)
13. Cole SP, Pinkoski MJ, Bhardwaj G, Deeley RG,. Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. Br J Cancer 1992; 65: 498-502.
14. Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M,. Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer 2009; 101: 287-294.
15. Zhong L, Wei K, Yang X, et al. Increased expression of Annexin A2 in oral squamous cell carcinoma. Arch Oral Biol 2009; 54: 17-25.
16. Pena-Alonso E, Rodrigo JP, Parra IC, et al. Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett 2008; 263: 89-98.
17. Liu JW, Shen JJ, Tanzillo-Swarts A, et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003; 22: 1475-1485. (Pubitemid 36390596)
18. Qi YJ, He QY, Ma YF, et al. Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. J Cell Biochem 2008; 104: 1625-1635.
19. Rodrigo Tapia JP, Pena Alonso E, García-Pedrero JM, et al. Annexin A2 expression in head and neck squamous cell carcinoma. [Article in Spanish] Acta Otorrinolaringol Esp 2007; 58: 257-262. (Pubitemid 47251510)
20. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-847. (Pubitemid 28331029)
21. Sobin LH, Wittekind Ch, editors. TNM classification of malignant tumours, 6th edition (UICC). Wiley-Liss: New York; 2002.
22. Fidler IJ,. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458. (Pubitemid 37328849)
23. Gupta GP, Massagué J,. Cancer metastasis: building a framework. Cell 2006; 127: 679-695. (Pubitemid 44781029)
24. Singh P,. Role of Annexin-II in GI cancers: interaction with gastrins/progastrins. Cancer Lett 2007; 252: 19-35. (Pubitemid 46759505)
25. Zhang F, Zhang L, Zhang B, et al. Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J Proteome Res 2009; 8: 5041-5047.
26. Velucci VF, Germino FJ, Reiss M,. Cloning of putative growth regulatory genes from primary human keratinocytes by substractive hybridization. Gene 1995; 166: 213-220. (Pubitemid 26008831)
27. Mohammad HS, Kurokohchi K, Yoneyama H, et al. Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol 2008; 33: 1157-1163.
28. Saris CJ, Tack BF, Kristensen T, Glenney JR Jr, Hunter T,. The cDNA sequence for the protein-tyrosine kinase substrate p36 (calpactin I heavy chain) reveals a multidomain protein with internal repeats. Cell 1986; 46: 201-212. (Pubitemid 16031687)
29. Gerke V, Weber K,. Identity of p36K phosphorylated upon Rous sarcoma virus transformation with a protein purified from brush borders; calcium-dependent binding to non-erythroid spectrin and F-actin. EMBO J 1984; 3: 227-233.
30. Gould KL, Woodgett JR, Isacke CM, Hunter T,. The protein-tyrosine kinase substrate p36 is also a substrate for protein kinase C in vitro and in vivo. Mol Cell Biol 1986; 6: 2738-2744.
31. Hubaishy I, Jones PG, Bjorge J, et al. Modulation of annexin II tetramer by tyrosine phosphorylation. Biochemistry 1995; 34: 14527-14534.
32. Hayes MJ, Moss SE,. Annexin 2 has a dual role as regulator and effector of v-Src in cell transformation. J Biol Chem 2009; 284: 10202-10210.
33. Frame MC, Brunton VG,. Advances in Rho-dependent actin regulation and oncogenic transformation. Curr Opin Genet Dev 2002; 12: 36-43. (Pubitemid 34094987)
34. Timpson P, Jones GE, Frame MC, Brunton VG,. Coordination of cell polarization and migration by the Rho family GTPases requires Src tyrosine kinase activity. Curr Biol 2001; 11: 1836-1846. (Pubitemid 33136523)
35. Calalb MB, Polte TR, Hanks SK,. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 1995; 15: 954-963.
36. Mitra SK, Schlaepfer DD,. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006; 18: 516-523. (Pubitemid 44332916)
37. de Graauw M, Tijdens I, Smeets MB, Hensbergen PJ, Deelder AM, van de Water B,. Annexin A2 phosphorylation mediates cell scattering and branching morphogenesis via cofilin activation. Mol Cell Biol 2008; 28: 1029-1040. (Pubitemid 351160059)
38. Braakhuis BJ, Senft A, de Bree R, et al. Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma. J Clin Pathol 2006; 59: 1254-1260. (Pubitemid 46048328)
39. Schlaepfer DD, Haigler HT,. Expression of annexins as a function of cellular growth state. J Cell Biol 1990; 111: 229-238.
40. Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C,. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 2009; 90: 177-185.
41. Ling Q, Jacovina AT, Deora A, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004; 113: 38-48. (Pubitemid 38541630)
42. Waisman DM,. Annexin II tetramer: structure and function. Mol Cell Biochem 1995; 149-150: 301-322.
43. Mai J, Waisman DM, Sloane BF,. Cell surface complex of cathepsin B/annexin II tetramer in malignant progression. Biochim Biophys Acta 2000; 1477: 215-230. (Pubitemid 30119902)
44. Zhao WQ, Waisman DM, Grimaldi M,. Specific localization of the annexin II heterotetramer in brain lipid raft fractions and its changes in spatial learning. J Neurochem 2004; 90: 609-620. (Pubitemid 38989391)
45. Oliferenko S, Paiha K, Harder T, et al. Analysis of CD44-containing lipid rafts: recruitment of annexin II and stabilization by the actin cytoskeleton. J Cell Biol 1999; 146: 843-854. (Pubitemid 29408909)
46. Yamada A, Irie K, Hirota T, Ooshio T, Fukuhara A, Takai Y,. Involvement of the annexin II-S100A10 complex in the formation of E-cadherin-based adherens junctions in Madin-Darby canine kidney cells. J Biol Chem 2005; 280: 6016-6027. (Pubitemid 40280085)
47. Hayes MJ, Shao D, Bailly M, Moss SE,. Regulation of actin dynamics by annexin 2. EMBO J 2006; 25: 1816-1826.